IMUNON Reports 2022 Financial Results and Provides Business Update
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
Conference Call Begins Today at 11:00 a.m. Eastern Time LAWRENCEVILLE, N.J., March 30, 2023 (GLOBE NEWSWIRE) -- IMUNON, Inc. (NASDAQ:...
SEATTLE, Wash. and VANCOUVER, British Columbia, March 30, 2023 (GLOBE NEWSWIRE) -- Achieve Life Sciences, Inc. (Nasdaq: ACHV), a late-stage...
Conference Call and Webcast Today at 4:30 p.m. ET 2022 Daré Key Portfolio Accomplishments: License Agreement with Organon to Commercialize...
Apollomics’ Class A ordinary shares and public warrants are expected to begin trading today on the Nasdaq Capital Market under the...
No quantifiable VYN201 plasma concentrations above the assay lower limit of quantification supports “soft” drug approach for topical pan-BD BET...
Acquired IXINITY® commercial payment and milestone economics from Aptevo TherapeuticsEMERYVILLE, Calif., March 30, 2023 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ:...
Brexafemme complements GSK’s industry-leading infectious disease portfolio with an FDA approved treatment for vulvovaginal candidiasisSCYNEXIS will receive an upfront payment...
OLINVYK-treated patients had a statistically significant 1.6 day (~27%) reduction in average overall hospital length of stay compared to matched...
CAMBRIDGE, Mass., March 30, 2023 (GLOBE NEWSWIRE) -- Omega Therapeutics, Inc. (Nasdaq: OMGA) (“Omega”), a clinical-stage biotechnology company pioneering the...
– Initiated registration program for SerpinPC to treat hemophilia B; Enrolling subjects in PRESent-5, observational study – – First subject...
LONDON and SALT LAKE CITY, March 30, 2023 (GLOBE NEWSWIRE) -- Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled...
ROCHESTER, N.Y., March 29, 2023 (GLOBE NEWSWIRE) -- Today, Casana - the industry leader in monitoring heart health through smart...
Study results support the disease-modifying potential of structurally targeted allosteric regulators of GCase for the treatment of Alzheimer’s diseaseBETHESDA, Md.,...
The BIIB080 Phase 1b clinical study is the first to show a reduction of this magnitude in tau PET across...
WARREN, N.J., March 29, 2023 (GLOBE NEWSWIRE) -- Aquestive Therapeutics, Inc. (NASDAQ:AQST), a pharmaceutical company advancing medicines to solve patients’...
Company Progresses Preclinical Next-Generation oral KIT Inhibitor for Mast Cell-Mediated Inflammatory DiseasesSAN FRANCISCO, March 29, 2023 (GLOBE NEWSWIRE) -- Third...
Uppsala, Sweden, March 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the regional proteomic...
UPPSALA, Sweden, March 29, 2023 (GLOBE NEWSWIRE) -- Olink Holding AB (publ) (Nasdaq: OLK) today announced that the regional proteomic...
VANCOUVER, British Columbia, March 29, 2023 (GLOBE NEWSWIRE) -- BetterLife Pharma Inc. (“BetterLife” or the “Company”) (CSE: BETR / OTCQB: BETRF...
ARLINGTON, Mass., March 29, 2023 (GLOBE NEWSWIRE) -- Kala Pharmaceuticals, Inc. (NASDAQ:KALA), a clinical-stage biopharmaceutical company dedicated to the research,...